Stopping cotrimoxazole during antiretroviral therapy raises risk of bacterial illness, malaria, Ugandan trial shows

Stopping cotrimoxazole prophylaxis increases the risk of serious bacterial infections and malaria, even at high CD4 cell counts, in people taking antiretroviral therapy in Uganda, results of a randomised trial show.

The results were presented on Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, by Professor Jonathan Levin of the UK’s Medical Research Council.

Read more:

COVID-19 Response Fund

There cannot be any complacency as to the need for global action.

With your help, we can plug critical gaps in the understanding of COVID-19. This will support global response efforts and help to save lives around the world.